Compare Cassava Sciences Inc (FLNA) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Nasdaq Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Nasdaq Inc trades at $94.82 (market cap $51.67B). The key difference: Nasdaq Inc is far larger — about 972.3× Cassava Sciences Inc's market cap, and Nasdaq Inc pays a 1.23% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NDAQ | |
|---|---|---|
Market Cap | $53.14M | $51.67B |
Sector | Health | Financials |
52-Week High | $4.64 | $100.98 |
52-Week Low | $1.09 | $76.85 |
Enterprise Value | -$33.43M | $58.73B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Nasdaq (NDAQ) trades at $94.72, up 7.62% with strong bullish momentum. The stock shows robust fundamentals with revenue growth to $8.26B in 2025 and net income margin of 23.03%. Recent earnings beats and a $0.31 dividend signal financial health. Technical indicators show overbought conditions but overall bullish sentiment.
Outlook remains positive with analyst consensus target of $105.60, though risks include market volatility and high valuation multiples. Investment opportunity lies in continued earnings growth and strategic positioning as a leading exchange operator.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
